search for




 

Review Article
Current Assessment and Management of Retinoblastoma
Clin Pediatr Hematol Oncol 2019;26:35-45.
Published online April 30, 2019
© 2019 Korean Society of Pediatric Hematology-Oncology and Korean Society for Pediatric Neuro-Oncology

Hee Won Chueh

Department of Pediatrics, Dong-A University Hospital, Dong-A University School of Medicine, Busan, Korea
Correspondence to: Hee Won Chueh
Department of Pediatrics, Dong-A University Hospital, 26 Deshingongwon-ro, Seo-gu, Busan 49201, Korea
Tel: +82-51-240-2648
Fax: +82-51-242-2765
E-mail: caaf80@empal.com
ORCID ID: orcid.org/0000-0002-3824-2334
Received March 13, 2019; Revised March 26, 2019; Accepted April 8, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Retinoblastoma is the most common intraocular malignancy in childhood. Diagnosis is currently made by ophthalmologists under general anesthesia as it is the gold standard for intraocular assessment. However, evaluations for extraocular disease are also
necessary. Treatment strategies vary according to the disease status. If a single eye is involved, the treatment goal is oriented to the removal of the tumor and prevention of relapse. In bilateral retinoblastoma, the main treatment goal is to save monocular vision and save life. This article will explore the available treatment options for retinoblastoma including enucleation, radiotherapy, local therapy, intravenous chemotherapy, intra-arterial injection and intra-vitreal injections. There were recent advances in our understanding on the genetic pathophysiology of the retinoblastoma protein gene in tumorigenesis, which may help developing future treatment. Early detection of retinoblastoma is important for prolonging survival and improving quality of life.
Keywords: Enucleation, Intra-arterial injection, Intra-vitreal chemotherapy, Retinoblastoma, Stem cell transplantation
References
  1. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
    Pubmed KoreaMed CrossRef
  2. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F, Desjardins L. Retinoblastoma. Orphanet J Rare Dis 2006;1:31.
    Pubmed KoreaMed CrossRef
  3. Kim JH, Yu YS. Incidence (1991-1993) and survival rates (1991-2003) of retinoblastoma in Korea. J Korean Ophthalmol Soc 2010;51:542-51.
    CrossRef
  4. McEvoy JD, Dyer MA. Genetic and epigenetic discoveries in human retinoblastoma. Crit Rev Oncog 2015;20:217-25.
    Pubmed KoreaMed CrossRef
  5. McEvoy J, Nagahawatte P, Finkelstein D, et al. RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget 2014;5:438-50.
    Pubmed KoreaMed CrossRef
  6. Dimaras H, Khetan V, Halliday W, et al. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 2008;17:1363-72.
    Pubmed CrossRef
  7. Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol 2013;14:327-34.
    Pubmed CrossRef
  8. Manning AL, Longworth MS, Dyson NJ. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev 2010;24:1364-76.
    Pubmed KoreaMed CrossRef
  9. Shinohara ET, DeWees T, Perkins SM. Subsequent malignancies and their effect on survival in patients with retinoblastoma. Pediatr Blood Cancer 2014;61:116-9.
    Pubmed CrossRef
  10. Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet 2012;379:1436-46.
    Pubmed CrossRef
  11. Yanoff M, Duker J. Part 8.1 Retinoblastoma. Ophthalmology. 4th ed. Amsterdam: Elsevier, 2013;887-94.
  12. Batra R, Abbott J, Jenkinson H, et al. Long-term retinoblastoma follow-up with or without general anaesthesia. Pediatr Blood Cancer 2014;61:260-4.
    Pubmed CrossRef
  13. Schueler AO, Hosten N, Bechrakis NE, et al. High resolution magnetic resonance imaging of retinoblastoma. Br J Ophthalmol 2003;87:330-5.
    Pubmed KoreaMed CrossRef
  14. Lee BJ, Kim JH, Kim DH, Park SH, Yu YS. The validity of routine brain MRI in detecting post-laminar optic nerve involvement in retinoblastoma. Br J Ophthalmol 2012;96:1237-41.
    Pubmed CrossRef
  15. Finger P, Harbour J, Murphree A. Chapter 52. Retinblastoma. AJCC Cancer Staging Manual. 7th ed. Berlin: Springer Science and Business Media, 2010;561-8.
    CrossRef
  16. Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol 1963;67:164-72.
    Pubmed
  17. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005;18:41-53.
    Pubmed CrossRef
  18. Chantada G, Doz F, Antoneli CB, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006;47:801-5.
    Pubmed CrossRef
  19. de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivelä T, Moll AC. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol 2014;15:1157-67.
    Pubmed CrossRef
  20. de Jong MC, Kors WA, de Graaf P, Castelijns JA, Moll AC, Kivelä T. The incidence of trilateral retinoblastoma: a systematic review and meta-analysis. Am J Ophthalmol 2015;160:1116-26.
    Pubmed CrossRef
  21. Villegas VM, Hess DJ, Wildner A, Gold AS, Murray TG. Retinoblastoma. Curr Opin Ophthalmol 2013;24:581-8.
    Pubmed CrossRef
  22. Bellaton E, Bertozzi AI, Behar C, et al. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma. Br J Ophthalmol 2003;87:327-9.
    Pubmed KoreaMed CrossRef
  23. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002;120:1653-8.
    Pubmed CrossRef
  24. Chojniak MM, Chojniak R, Testa ML, et al. Abnormal orbital growth in children submitted to enucleation for retinoblastoma treatment. J Pediatr Hematol Oncol 2012;34:e102-5.
    Pubmed CrossRef
  25. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol 2010;21:203-12.
    Pubmed CrossRef
  26. Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth Group Vb retinoblastoma. Arch Ophthalmol 2004;122:1316-23.
    Pubmed CrossRef
  27. Choi SY, Kim MS, Yoo S, et al. Long term follow-up results of external beam radiotherapy as primary treatment for retinoblastoma. J Korean Med Sci 2010;25:546-51.
    Pubmed KoreaMed CrossRef
  28. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009;27:2356-62.
    Pubmed KoreaMed CrossRef
  29. Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009;101:581-91.
    Pubmed KoreaMed CrossRef
  30. Kleinerman RA, Tucker MA, Sigel BS, Abramson DH, Seddon JM, Morton LM. Patterns of cause-specific mortality among 2053 survivors of retinoblastoma, 1914-2016. J Natl Cancer Inst 2019. [Epub ahead of print]
    Pubmed CrossRef
  31. Chang JW, Yu YS, Kim JY, et al. The clinical outcomes of proton beam radiation therapy for retinoblastomas that were resistant to chemotherapy and focal treatment. Korean J Ophthalmol 2011;25:387-93.
    Pubmed KoreaMed CrossRef
  32. Shields CL, Shields JA, De Potter P, et al. Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment. Ophthalmology 1993;100:216-24.
    Pubmed CrossRef
  33. Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R. Retinoblastoma: review of current management. Oncologist 2007;12:1237-46.
    Pubmed CrossRef
  34. Dunkel IJ, Jubran RF, Gururangan S, et al. Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer 2010;54:384-7.
    Pubmed CrossRef
  35. Shields CL, Lally SE, Leahey AM, et al. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol 2014;25:374-85.
    Pubmed CrossRef
  36. Shields CL, Kaliki S, Al-Dahmash S, et al. Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation. Retina 2013;33:2103-9.
    Pubmed CrossRef
  37. Jaradat I, Mubiden R, Salem A, Abdel-Rahman F, Al-Ahmad I, Almousa A. High-dose chemotherapy followed by stem cell transplantation in the management of retinoblastoma: a systematic review. Hematol Oncol Stem Cell Ther 2012;5:107-17.
    Pubmed CrossRef
  38. Lee SH, Yoo KH, Sung KW, et al. Tandem high-dose chemotherapy and autologous stem cell rescue in children with bilateral advanced retinoblastoma. Bone Marrow Transplant 2008;42:385-91.
    Pubmed CrossRef
  39. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004;9:69-73.
    Pubmed CrossRef
  40. Francis JH, Gobin YP, Dunkel IJ, et al. Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. PLoS One 2013;8:e72441.
    Pubmed KoreaMed CrossRef
  41. Marr BP, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH. Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol 2012;96:1300-3.
    Pubmed CrossRef
  42. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 2010;117:1623-9.
    Pubmed CrossRef
  43. Ericson L, Karlberg B, Rosengren BH. Trials of intravitreal injections of chemotherapeutic agents in rabbits. Acta Ophthalmol (Copenh) 1964;42:721-6.
    Pubmed CrossRef
  44. Kivelä T, Eskelin S, Paloheimo M. Intravitreal methotrexate for retinoblastoma. Ophthalmology 2011;118:1689.
    Pubmed CrossRef
  45. Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol 2014;132:319-25.
    Pubmed CrossRef
  46. Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond) 2013;27:253-64.
    Pubmed KoreaMed CrossRef
  47. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol 2012;130:1268-71.
    Pubmed CrossRef
  48. Francis JH, Marr BP, Brodie SE, Gobin YP, Abramson DH. Tethered vitreous seeds following intravitreal melphalan for retinoblastoma. JAMA Ophthalmol 2014;132:1024-5.
    Pubmed CrossRef
  49. Friedman DN, Sklar CA, Oeffinger KC, et al. Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Pediatr Blood Cancer 2013;60:694-9.
    Pubmed CrossRef
  50. Choi JY, Kang HJ, Lee JW, et al. Very late relapse of bilateral retinoblastoma. J Pediatr Hematol Oncol 2015;37:e264-7.
    Pubmed CrossRef
  51. Rodriguez-Galindo C. The basics of retinoblastoma: back to school. Pediatr Blood Cancer 2011;57:1093-4.
    Pubmed CrossRef
  52. Gallie BL, Zhao J, Vandezande K, White A, Chan HS. Global issues and opportunities for optimized retinoblastoma care. Pediatr Blood Cancer 2007;49:1083-90.
    Pubmed CrossRef
  53. Skalet AH, Gombos DS, Gallie BL, et al. Screening children at risk for retinoblastoma: consensus report from the american association of ophthalmic oncologists and pathologists. Ophthalmology 2018;125:453-8.
    Pubmed CrossRef


April 2019, 26 (1)
Full Text PDF
Citation
Send to a friend
Twitter
Facebook

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Hee Won Chueh